Navigation Links
Inclinix, Inc. and JSW Life Sciences Announce Formal Strategic Partnership for European Clinical Trial Enrollment
Date:2/21/2012

WILMINGTON, N.C., Feb. 21, 2012 /PRNewswire/ -- Inclinix, Inc. and JSW Life Sciences announce today their formal strategic partnership. This partnership places Inclinix offices in Graz, Austria and expands Inclinix by over one hundred enrollment professionals in Eastern and Western Europe.

"As Inclinix has experienced significant growth over the past year, it has been important for us to identify a European partner that shares our philosophy and performance enrollment model," explains J. Tobin Geatz, Inclinix President and CEO. "We are pleased to have such an excellent partner as JSW Life Sciences to support the enrollment of all of our studies in Europe."

The Inclinix Clinical Enrollment Manager (CEM) programs offer a unique approach to global clinical trial enrollment. CEMs provide in-field enrollment support to investigative sites, focusing on identifying qualified study candidates not only from within the sites' practices, but from the surrounding medical and patient communities as well.

Dr. Manfred Windisch, CEO of JSW Life Sciences, states, "We are excited to combine our clinical expertise and native-language teams with Inclinix's enrollment experience. We look forward to many successful enrollment campaigns through this partnership."

About Inclinix
Inclinix, Inc. specializes in customized Phase I-IV clinical enrollment solutions for pharmaceutical, biotechnology, and medical device organizations. Clients benefit from twelve years of experience in multiple therapeutic areas. Inclinix delivers a customized, site-focused approach to patient recruitment ensuring every available study candidate is identified, qualified and enrolled. By combining an in-field approach with highly targeted patient outreach, Inclinix creates effective enrollment strategies within a performance model. www.inclinix.com

About JSW Life Sciences
JSW Life Sciences is a full service contract research organization. The company performs preclinical as well as clinical research. The preclinical research department focuses on drug development for neurodegenerative diseases. The profound expertise in neuroscience and more than a decade of experience in contract research result in a sustainable advantage for the customer. Validated transgenic & non-transgenic in vivo & in vitro models to address new as well as already established drug targets in neurodegenerative diseases are available. 

The clinical research team ensures an efficient development process from First-in-Man (Phase I) up to and including Post-Marketing-Surveillance-Studies (Phase IV). Our customers benefit from the competent teams at JSW, the use of innovative technology as well as scientific and clinical expertise together with a worldwide network. www.jsw-lifesciences.com   


'/>"/>
SOURCE Inclinix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
Breaking Medicine News(10 mins):